NEW
YORK, May 22, 2025 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders
of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).
Shareholders who purchased shares of ATNM during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=149521&from=4
CLASS PERIOD: October 31,
2022 to August 2, 2024
ALLEGATIONS: The complaint alleges that
during the class period, Defendants issued materially false and/or
misleading statements and/or failed to disclose that: (1) the
Company's data from the Phase 3 Sierra trial was unlikely to
satisfy the FDA's guidelines for the acceptance and approval of the
Company's targeted radiotherapy, Iomab-B BLA; (2) the additional
analyses, including long-term follow-ups that purportedly
demonstrated a trend towards improved Overall Survival that the
Company provided to the FDA in an attempt to mitigate the Sierra
Trial's poor OS data were unlikely to satisfy the FDA's guidelines
for the acceptance and approval of the Company's Iomab-B BLA; (3)
as a result, the FDA would likely refuse to review the Iomab-B BLA
or, if it did consider that BLA, that the application in its
current form was unlikely to be approved; and (4), as a result,
defendants' positive statements about the Company's business,
operations, and prospects were materially misleading and/or lacked
a reasonable basis.
DEADLINE: May 27, 2025
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=149521&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of ATNM during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is May 27, 2025. There is no cost or
obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-may-27-2025-in-actinium-lawsuit--atnm-302462503.html
SOURCE The Gross Law Firm